The National Pharmaceutical Pricing Authority has capped trade margins on 137 non-scheduled cancer drugs, leading to a 38% average price reduction. However, 159 high-cost patented medications remain unchanged. The move aims to improve affordability, though critics argue the margin caps remain too high compared to essential medicines.
The National Pharmaceutical Pricing Authority (NPPA) is set to implement new trade margin rules for 137 non-scheduled anti-cancer drugs starting November 9. This regulatory update is designed to limit the markup that distributors and retailers can add to these medications. An analysis of 643 drug packs shows that, on average, prices have dropped by roughly 38%. While this is a step toward making cancer care more accessible, the impact is uneven, as nearly 25% of the drugs listed have seen no change in their maximum retail prices (MRP).
The primary focus of this order is on 'trade margin rationalization.' This means the government has set a ceiling on the gap between what a manufacturer sells the drug for and the final price a patient pays. Currently, the order caps the aggregate trade margin at 30% of the MRP. This is intended to prevent excessive price padding along the supply chain. However, the policy effectively allows for a markup of about 42.86% over the manufacturer's sale price.
One of the most notable aspects of this implementation is the exclusion of several high-cost patented therapies from price reductions. Medications like Keytruda, used in immunotherapy, and targeted therapies such as Tagrisso, Alecensa, Voranigo, and Koselugo continue to be sold at their previous high prices. These drugs often cost several lakhs per injection or treatment cycle. Because these are largely patented and specialized imported products, their pricing structures often differ from the more commoditized generic drugs typically found in the essential medicines category.
Critics, including petitioner KC Jain, have questioned the effectiveness of these caps. The central argument is that a 30% margin cap on these non-scheduled drugs is significantly more lenient than the 16% retailer margin limit currently applied to 'scheduled' drugs—those considered essential medicines under the Drug Price Control Order (DPCO). This gap leads to a situation where the intended affordability for patients may not be fully realized for high-end treatments.
For investors and market observers, the key nuance lies in the classification of the drugs. Companies with a large portfolio of generic oncology drugs may face more pressure on margins due to these caps, as their products are more sensitive to price regulations. Conversely, manufacturers of high-end patented therapies appear to retain more pricing flexibility for now, as the government seeks to balance patient affordability with the high research and import costs associated with these advanced treatments. The next important monitorable will be how effectively this 30% cap is enforced across the supply chain after November 9 and whether the NPPA decides to tighten margins further for premium categories in the future.